Jiangsu Hengrui Pharmaceuticals(600276.SH): The first-class innovative drug Haquibpaponile has added a new indication for ethanolamine tablets.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company has received notification from the National Medical Products Administration approving the addition of a new indication for the company's independently developed innovative drug Haiqupopa ethylenediamine tablets. The approved indication is: This product is suitable for use in combination with immunosuppressive therapy for patients aged 15 and above with newly diagnosed severe aplastic anemia (SAA). Haiqupopa ethylenediamine tablets were approved for marketing in 2021 for two indications: 1. This product is suitable for adult patients with chronic primary immune thrombocytopenia (ITP) who have not responded well to previous treatments such as corticosteroids and immunoglobulins. 2. This product is suitable for adult patients with severe aplastic anemia (SAA) who have not responded well to immunosuppressive therapy (IST).